Tags

Type your tag names separated by a space and hit enter

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
Diabetes Ther. 2016 Sep; 7(3):583-90.DT

Abstract

INTRODUCTION

The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM.

METHODS

A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.

RESULTS

Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001).

CONCLUSION

A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide.

FUNDING

Sanofi.

CLINICAL TRIAL NUMBERS

NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S).

Authors+Show Affiliations

Lund University, Lund, Sweden. bo.ahren@med.lu.se.National Centre of Endocrinology, Moscow, Russian Federation.Lariboisière Hospital, Paris, France.University of Bari Aldo Moro, Bari, Italy.Hospital General de Segovia, Segovia, Spain.Medical University of Vienna, Vienna, Austria.Artech Information Systems, LLC, Morristown, NJ, USA.Sanofi, Bridgewater, NJ, USA.Hospital Universitario San José, Popayán, Colombia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27319011

Citation

Ahrén, Bo, et al. "Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin With Lixisenatide Treatment in Type 2 Diabetes Mellitus: a Post Hoc Analysis." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, vol. 7, no. 3, 2016, pp. 583-90.
Ahrén B, Galstyan G, Gautier JF, et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016;7(3):583-90.
Ahrén, B., Galstyan, G., Gautier, J. F., Giorgino, F., Gomez-Peralta, F., Krebs, M., Nikonova, E., Stager, W., & Vargas-Uricoechea, H. (2016). Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 7(3), 583-90. https://doi.org/10.1007/s13300-016-0179-6
Ahrén B, et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin With Lixisenatide Treatment in Type 2 Diabetes Mellitus: a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016;7(3):583-90. PubMed PMID: 27319011.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. AU - Ahrén,Bo, AU - Galstyan,Gagik, AU - Gautier,Jean-Francois, AU - Giorgino,Francesco, AU - Gomez-Peralta,Fernando, AU - Krebs,Michael, AU - Nikonova,Elena, AU - Stager,William, AU - Vargas-Uricoechea,Hernando, Y1 - 2016/06/18/ PY - 2016/04/07/received PY - 2016/6/20/entrez PY - 2016/6/20/pubmed PY - 2016/6/20/medline KW - Glucagon KW - Glucagon-like peptide-1 receptor agonist KW - Glycemic control KW - Lixisenatide KW - Prandial KW - Type 2 diabetes mellitus SP - 583 EP - 90 JF - Diabetes therapy : research, treatment and education of diabetes and related disorders VL - 7 IS - 3 N2 - INTRODUCTION: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM. METHODS: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c. RESULTS: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001). CONCLUSION: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide. FUNDING: Sanofi. CLINICAL TRIAL NUMBERS: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S). SN - 1869-6953 UR - https://www.unboundmedicine.com/medline/citation/27319011/Postprandial_Glucagon_Reductions_Correlate_to_Reductions_in_Postprandial_Glucose_and_Glycated_Hemoglobin_with_Lixisenatide_Treatment_in_Type_2_Diabetes_Mellitus:_A_Post_Hoc_Analysis_ L2 - https://dx.doi.org/10.1007/s13300-016-0179-6 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.